CD274 and thyroid gland undifferentiated (anaplastic) carcinoma: Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer